TNF Inhibitors Likely Source of 11 Pediatric Lymphoma Deaths

Here we go again.

In June 2008, the FDA announced it was looking into a possible link between TNF inhibitors and cancer, and what it found was almost 50 cases of malignant pediatric cancer and almost 150 cases of both pediatric and adult leukemia. Lymphomas ultimately claimed the lives of 11 of those children and teenagers.

These drugs already have a black-box warning as being potentially cancer-causing—a black-box warning is an FDA warning on the drug's label, named so because it's surrounded by a black border—now the FDA says the warning needs to be changed to include the risk of pediatric lymphoma and other pediatric cancers.

This is likely another sickening case of the powerful drug companies influencing premature FDA approval of their drugs before all the risks had been properly explored, for reasons grounded in nothing but greed.

What are TNF Inhibitors?

TNF inhibitors, also called TNF blockers, are a class of immune-disease drugs used to treat a number of inflammatory and autoimmune diseases, including psoriasis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, and juvenile rheumatoid arthritis. These diseases cause the excess production of tumor necrosis factor alpha (TNF), a protein. TNF inhibitors block the action of the protein.

The drugs at issue are:

Remicade (infliximab), made by Centocor
Enbrel (etanercept), made by Amgen
Humira (adalimumab), made by Abbott Laboratories
Cimzia (Certolizumab pegol), made by UCB
Simponi (Golimumab), made by Centocor

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap